Publication: European Pharmaceutical Review

First reported 8 hours ago - Updated 39 mins ago - 1 reports

Pfizer enters into agreement to acquire Baxter’s portfolio of marketed vaccines

Pfizer Inc. today announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in ... [Published European Pharmaceutical Review - 8 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

CHMP issues positive opinion for intravenous formulation of Merck’s NOXAFIL® (posaconazole)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the of the has adopted a positive opinion recommending approval of a new, investigational intravenous (IV) formulation of NOXAFIL® (posaconazole).The CHMP positive ... [Published European Pharmaceutical Review - 8 hours ago]
First reported Jul 29 2014 - Updated 10 hours ago - 1 reports

New blockbuster drugs to more than triple acute coronary syndrome treatment market value by 2023, says GlobalData

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting ... [Published European Pharmaceutical Review - Jul 29 2014]
First reported Jul 29 2014 - Updated 19 hours ago - 1 reports

Roche’s Gazyvaro approved in Europe for patients with the most common type of leukemia

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia who have ... [Published European Pharmaceutical Review - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Phase 2 COSMOS study results published in The Lancet demonstrate efficacy and safety of Janssen’s once-daily imeprevir

Results from the Phase 2 COSMOS (Combination OfSiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) clinical study were published July 28 in The Lancet, demonstrating that 92 percent of genotype 1 chronic hepatitis C virus (HCV) adult patients ... [Published European Pharmaceutical Review - Jul 29 2014]
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Abbott to showcase innovations to help labs solve health care challenges at the American Association for Clinical Chemistry Lab Expo

Clinical laboratories around the world are helping to improve patient care while navigating an evolving health care environment. To help laboratories with increasing demands, Abbott (NYSE: ABT) is developing diagnostic solutions for today and tomorrow, ... [Published European Pharmaceutical Review - Jul 29 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

FDA approves Flonase allergy relief for sale over-the-counter in the United States

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the U.S. has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray), containing the No. 1 prescribed allergy treatment ingredient1, as an over-the-counter (OTC) treatment for temporary ... [Published European Pharmaceutical Review - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

PLEGRIDY™ (Peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis

Today Biogen Idec (NASDAQ: BIIB) announced that the has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). ... [Published European Pharmaceutical Review - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Sucampo announces publication of NICE recommendation for AMITIZA® (Lubiprostone)

Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ: SCMP), a global biopharmaceutical company, today announced that the United Kingdom’s National Institute of Health and Care Excellence (NICE) has published the technology appraisal guidance recommending ... [Published European Pharmaceutical Review - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination with darunavir/ritonavir

ViiV Healthcare today presented, at the 20th International AIDS Congress in Melbourne, Australia, the analysis of the 48-week results from the phase III MODERN study comparing maraviroc (MVC; marketed as Celsentri® /Selzentry®) dosed once daily with darunavir/ritonavir ... [Published European Pharmaceutical Review - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

GE introduces new Sievers* M9 Total Organic Carbon Analyzer for ultrapure and process waters

GE (NYSE: GE) today announced the release of its new Sievers* M9 Total Organic Carbon (TOC) Analyzer, which has been designed to measure TOC in a broad range of samples from ultrapure water to process waters. The new M9 Analyzer enhances productivity ... [Published European Pharmaceutical Review - Jul 21 2014]
First reported Jul 03 2014 - Updated Jul 04 2014 - 2 reports

Pharmaceutical powders characterisation – the need for a multivariate approach

Powders and bulk materials are widely used in industry as raw materials, intermediates and finished products. Indeed, over 60% of the value of pharmaceutical sales worldwide is accounted for by pharmaceutical powders, typically as tablet/capsule/sachet ... [Published European Pharmaceutical Review - Jul 04 2014]

More Content

All (45) | News (45) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Pfizer enters into agreement to acquire Baxter’... [Published European Pharmaceutical Review - 8 hours ago]
CHMP issues positive opinion for intravenous fo... [Published European Pharmaceutical Review - 8 hours ago]
Phase 2 COSMOS study results published in The L... [Published European Pharmaceutical Review - Jul 29 2014]
New blockbuster drugs to more than triple acute... [Published European Pharmaceutical Review - Jul 29 2014]
Abbott to showcase innovations to help labs sol... [Published European Pharmaceutical Review - Jul 29 2014]
Roche’s Gazyvaro approved in Europe for patient... [Published European Pharmaceutical Review - Jul 29 2014]
FDA approves Flonase allergy relief for sale ov... [Published European Pharmaceutical Review - Jul 25 2014]
PLEGRIDY™ (Peginterferon beta-1a) approved in t... [Published European Pharmaceutical Review - Jul 24 2014]
Sucampo announces publication of NICE recommend... [Published European Pharmaceutical Review - Jul 23 2014]
ViiV Healthcare presents phase III data compari... [Published European Pharmaceutical Review - Jul 22 2014]
GE introduces new Sievers* M9 Total Organic Car... [Published European Pharmaceutical Review - Jul 21 2014]
Teva completes acquisition of Labrys [Published European Pharmaceutical Review - Jul 21 2014]
Trametinib (Mekinist™) and dabrafenib (Tafinlar... [Published European Pharmaceutical Review - Jul 18 2014]
Roche announces phase II clinical results of cr... [Published European Pharmaceutical Review - Jul 17 2014]
Biogen Idec and Yahoo Health spotlight visionar... [Published European Pharmaceutical Review - Jul 16 2014]
FDA grants Roche’s Avastin Priority Review for ... [Published European Pharmaceutical Review - Jul 15 2014]
Abbott to sell its developed markets branded ge... [Published European Pharmaceutical Review - Jul 14 2014]
Collaboration between Glatt and Innopharma labs... [Published European Pharmaceutical Review - Jul 11 2014]
Abbott builds long-term commitment in China [Published European Pharmaceutical Review - Jul 11 2014]
Judit Makara wins Boehringer Ingelheim’s FENS A... [Published European Pharmaceutical Review - Jul 07 2014]
qPCR: In-depth focus 2014 [Published European Pharmaceutical Review - Jul 04 2014]
Japan becomes first country to approve Roche’s ... [Published European Pharmaceutical Review - Jul 04 2014]
Using self-amplifying mRNA vaccines to facilita... [Published European Pharmaceutical Review - Jul 04 2014]
Polymorphism – Polymorph myths and misperceptions [Published European Pharmaceutical Review - Jul 04 2014]
NMR – Recent developments for isotope profiling [Published European Pharmaceutical Review - Jul 04 2014]
Techniques to preserve product quality in pharm... [Published European Pharmaceutical Review - Jul 04 2014]
Issue #3 2014 – Digital edition [Published European Pharmaceutical Review - Jul 04 2014]
Pharmaceutical powders characterisation – the n... [Published European Pharmaceutical Review - Jul 04 2014]
Ebola cases in West Africa continue to rise [Published European Pharmaceutical Review - Jul 03 2014]
Mass spectrometry-based metabolics – an exclusi... [Published European Pharmaceutical Review - Jul 03 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.